Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro

Figure 3

Effects of LEDGF/p75 and bcl-2 on daunorubicin-induced apoptosis. Flp-In 293 cells were transfected with control vector pcDNA3.1 or vectors containing either LEDGF/p75 or bcl-2. All transfected cells treated with vehicle alone (Ctl) had normal morphology. After treatment with 0.5 μM daunorubicin (DNR) for 16 h only 22% of the cells transfected with control vector appeared morphologically viable, against 47 and 42% for cells transfected with either LEDGF/p75 or bcl-2. Also cells treated with 5 μM daunorubicin for 1 h were protected by transfection with either LEDGF/p75 or bcl-2. Cell viability was analysed as described in the Materials and Methods section. Results are presented as the mean of viable cells ± SEM of separate experiments performed in triplicate (n = 3).

Back to article page

Molecular Cancer

ISSN: 1476-4598